Production (Stage)
Akebia Therapeutics, Inc.
AKBA
$2.86
$0.031.06%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -45.31M | -69.41M | -45.99M | -40.44M | -43.03M |
| Total Depreciation and Amortization | 32.64M | 41.70M | 41.78M | 41.82M | 41.81M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 32.11M | 26.73M | 18.36M | 8.86M | 8.64M |
| Change in Net Operating Assets | -54.26M | -39.68M | -52.65M | -49.20M | -32.70M |
| Cash from Operations | -34.81M | -40.66M | -38.50M | -38.97M | -25.28M |
| Capital Expenditure | -51.00K | -33.00K | -31.00K | -29.00K | -- |
| Sale of Property, Plant, and Equipment | 172.00K | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 121.00K | -33.00K | -31.00K | -29.00K | -- |
| Total Debt Issued | 18.00M | 45.00M | 45.00M | 45.00M | 37.00M |
| Total Debt Repaid | -835.00K | -37.10M | -45.10M | -45.10M | -52.73M |
| Issuance of Common Stock | 89.55M | 43.03M | 27.42M | 25.73M | 25.71M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -585.00K | -1.27M | -1.27M | -750.00K | -750.00K |
| Cash from Financing | 106.13M | 49.66M | 26.05M | 24.88M | 9.24M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 71.44M | 8.97M | -12.48M | -14.13M | -16.04M |